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Hemodialysis and L-arginine, but not D-arginine, correct renal failure-
associated endothelial dysfunction. In end-stage renal failure (ESRF)
symptomatic hemodialysis-related hypotension may prevent effective pro-
vision of renal replacement therapy. Endogenous inhibitors of nitric oxide
synthase accumulate in ESRF and are cleared by dialysis. We, therefore,
hypothesised that removal of these inhibitors by hemodialysis would
increase endothelial nitric oxide generation and promote venodilation. In
vivo responses of norepinephrine preconstricted dorsal hand veins to
locally active doses of acetylcholine (an activator of nitric oxide synthase)
and glyceryl trinitrate (GTN; a nitric oxide donor) were examined in
patients undergoing maintenance hemodialysis for ESRF and in healthy
age- and sex-matched controls. Patient studies were undertaken before
and after dialysis. Studies before dialysis were repeated with co-infusion of
either L-arginine or its inactive enantiomer D-arginine. Venodilation in
response to acetylcholine was impaired before, and corrected by, dialysis
whereas venodilation to GTN was similar before and after dialysis.
Venodilation in response to acetylcholine before dialysis was restored by
co-infusion of L- but not D-arginine. Therefore, patients with ESRF
undergoing hemodialysis have impaired acetylcholine-mediated venodila-
tion consistent with the accumulation in ESRF of functionally important
inhibitors of nitric oxide synthase that are cleared by dialysis.
Symptomatic hypotension occurs in more than 25% of hemo-
dialysis sessions, and may substantially restrict the amount of fluid
that can be removed [1]. Frequently occurring dialysis-associated
hypotension impedes regular and efficient renal replacement
therapy. Many mechanisms have been proposed as the cause of
this clinical problem, all of which invoke an inappropriate physi-
ological response to hypovolemia [2, 3]. Abnormalities of the
responses of both resistance and capacitance vessels to hypovole-
mia have been demonstrated during hemodialysis. Forearm ve-
nous capacitance has been shown to increase during acetate and
bicarbonate dialysis [4, 5]. Inappropriately small reflex increases
in peripheral vascular resistance to hypovolemia have also been
demonstrated during hemodialysis, but not during fluid removal
by ultrafiltration alone [1, 6]. These studies are consistent with the
hypothesis that an alteration of venous and arterial responses to
hypovolemia is due to clearance, by dialysis, of a circulating
vasoconstrictor agent.
Vascular endothelial cells generate a potent and labile vasodi-
lator substance, nitric oxide [7–9], through the action of a
constitutive nitric oxide synthase enzyme acting on its stereospe-
cific substrate, L-arginine [10, 11]. In end-stage renal failure there
is accumulation of methylguanidine [12], and of other naturally
occurring methylated analogs of L-arginine, such as NG, NG,
dimethyl-arginine otherwise known as asymmetrical dimethyl
arginine (ADMA) and NG, L-monomethyl arginine (L-NMMA)
[13, 14]. Methylguanidine [15, 16], ADMA [17] and L-NMMA [8,
18] are competitive inhibitors of nitric oxide synthase. In addition,
ADMA is cleared by hemodialysis [14, 19] and causes vasocon-
striction in ex vivo studies at similar concentrations to those found
in some patients with end-stage renal failure [20]. ADMA also
causes local vasoconstriction when infused into healthy subjects
[14, 17]. Furthermore, these nitric oxide synthase inhibitors may
act synergistically [14, 19].
We tested the hypotheses that: (i) end-stage renal failure is
associated with endothelial dysfunction; (ii) endothelial dysfunc-
tion is due to the presence of a dialysable substance and so would
be improved by dialysis; and (iii) such endothelial dysfunction,
being caused by inhibitors of nitric oxide synthase, would be
reversed by L- but not D-arginine.
Dialysis related hypotension appears to be predominantly me-
diated by changes within the capacitance system [5, 21]. In
addition, cutaneous limb veins are under sympathetic venomotor
control [22], indicating that the responses in hand veins should
reflect responses found in those vessels that control venous
capacitance and cardiac preload [23, 24]. Furthermore, investiga-
tion of hand veins avoids the confounding effects associated with
vascular hypertrophy and other structural changes that may occur
in the resistance vessels of patients with hypertension [23].
Therefore, we chose to examine endothelial function in dorsal
hand veins. These studies have the advantage of using locally
active doses of drugs and do not require systemic doses which may
obscure any direct vascular action by direct effects on other
organs, such as the heart and kidney, or activate reflex mecha-
nisms due to changes in blood pressure. We used the muscarinic
agonist, acetylcholine, as an endothelium dependent venodilator
[8, 9, 25] and glyceryl trinitrate (GTN), as an endothelium
independent venodilator [8]. Studies were performed in patients
with end-stage renal failure undergoing hemodialysis and healthy
age- and sex-matched control subjects. In order to eliminate
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potential confounding factors that may influence the interpreta-
tion of the vascular responses to acetylcholine, we also measured
plasma concentrations of arginine, the substrate for nitric oxide
synthase; cholesterol, which may influence endothelial responsive-
ness to acetylcholine; and cholinesterase, which by degrading
acetylcholine may influence the observed vascular responsiveness,
both before and after dialysis.
METHODS
Subjects
Twelve consecutive patients with established end-stage renal
failure (Table 1) were recruited for the study. All patients had
been maintained on renal replacement therapy three times weekly
for at least three months, at the Western General Hospital or
Royal Infirmary, Edinburgh. Patients were excluded if they had a
diagnosis of diabetes mellitus, had commenced on human recom-
binant erythropoietin within the preceding three months, or were
taking alpha receptor antagonists or nitrovasodilators.
All patients continued with their regular dialysis prescription
administered using Fresenius A 2008 C dialysis machines with
cuprophan (Alwall GFE 11 or 18; Gambro Ltd, Sidcup, UK) or
cellulose-acetate membranes (180 MCA; Althin Ltd, Cambridge,
UK) (Table 1). All patients were dialyzed against bicarbonate.
Two patients (Table 1) were taking antihypertensive medication
(nifedipine and metoprolol) and their doses were not changed
during the study. Diet was high in calories but limited to a daily
intake of 1 g/kg body wt protein, 80 to 100 mmol sodium and 1
mmol/kg body wt potassium, with a daily fluid restriction of 500 ml
plus a volume equal to urine output in the previous 24 hours.
Eight age- and sex-matched control subjects were also recruited.
All studies were conducted with the approval of the Lothian
Research Ethics Committee and all subjects gave their written
informed consent to participate. All subjects avoided caffeine-
containing drinks or cigarettes on the day of each study, and were
fasted for at least three hours before each study.
Drugs
Locally, but not systemically, active doses of norepinephrine (3
to 192 pmol/min; Sterling-Winthrop, Guildford, UK) [23], acetyl-
choline (0.1 to 100 nmol/min; IOLAB, Bracknell, UK) [8], GTN
(0.3 to 10 pmol/min; Schwartz Pharma Ltd, Chesham, UK) [8],
L-arginine hydrochloride (100 nmol/min; Stockport Pharmaceu-
ticals, Stepping Hill Hospital, UK) [8] and D-arginine hydrochlo-
ride (100 nmol/min; Clinalfa AG, Switzerland) [8] were infused.
All drugs were dissolved in saline. Ascorbic acid (Evans Medical,
Horsham, UK) at a final concentration of 100 mg/ml was added to
the norepinephrine solutions to prevent degradation by oxidation
[26].
Intravenous administration
A selected dorsal hand vein on the non-fistula arm of the
hemodialysis patients, or the non-dominant arm in controls, was
cannulated in the direction of flow with a 23 SWG cannula
(Abbott, Sligo, Republic of Ireland), without the use of local
anesthesia, for the purpose of intravenous infusion of drugs. The
total rate of infusion was maintained constant throughout all of
the studies at 20 ml/hr.
Measurements
Dorsal hand vein diameter. The infused arm was supported
above the level of the heart by means of an arm rest. Internal
diameter of the dorsal hand vein, distended by inflation of an
upper arm cuff to 30 mm Hg, was measured by the technique of
Aellig [27]. In brief, a lightweight magnetized rod rested on the
summit of the infused vein ;1 cm downstream from the tip of the
infusion cannula. This rod passed through the core of a linear
variable differential transformer (LVDT; Lucas Control Systems
Products, Slough, UK) supported above the hand by means of a
small tripod, the legs of which rested on areas of the dorsum of the
hand free of veins. Local changes in vein size resulted in displace-
ment of the rod causing a linear change in the voltage generated
by the LVDT and allowed the determination of the internal
diameter of the vein. Voltage output from the LVDT was
transferred to a Macintosh personal computer file using a MacLab
analog-digital converter and Chart software (v. 3.2.8; both from
AD Instruments, Castle Hill, NSW, Australia).
Blood pressure. Arterial pressure was measured using a well-
validated semi-automated oscillometric method (Takeda UA 751)
Table 1. Patient characteristics
Patient Age Sex Diagnosis
Hours
dialyzed
Artificial
kidney
Pre-HD and
Post-HD
Pre-HD and
Pre-HD 1 L-arg
Pre-HD and
Pre-HD 1 D-arg Vasoactive medication
1 33 M Mesangiocapillary GN 4.5 GFE 18 Y Y N N
2 26 M Alport’s syndrome 4.5 GFE 18 Y Y N N
3 63 M Polycystic kidney disease 4 GFE 11 Y N N N
4 36 M Chronic pyelonephritis 4.5 GFE 18 Y Y Y N
5a 61 F Bilateral nephrectomy for
tumor
4 GFE 11 Y Y N N
6a 63 F Polycystic kidney disease 3 GFE 11 Y Y Y N
7a 45 M Mesangioproliferative
GN
3 GFE 11 Y Y N metoprolol1nifedipine
8 26 M Obstructive uropathy 4 GFE 18 Y Y Y metoprolol1nifedipine
9 65 M Polycystic kidney disease 4 180 MCA N Y N N
10a 26 F Chronic pyelonephritis 3.5 GFE 11 N N Y N
11 28 F Chronic pyelonephritis 4 GFE 11 N N N N
12 62 M Alport’s syndrome 3.5 GFE 11 N N N N
Abbreviations are: glomerulonephritis (GN), hemodialysis (HD), GFE 11 or 18 (cuprophan membrane; Gambro), 180 MCA (cellulose-acetate
membrane; Althin). All patients had the dose response to norepinephrine ‘before’ dialysis except a which were undertaken after dialysis. Y 5 yes; N
5 no.
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[28, 29] in the non-fistula arm of patients with end-stage renal
failure and in the non-infused arm of control subjects.
Hemoglobin and hematocrit. Hemoglobin was measured using
a Coulter STKS analyzer (Coulter Electronics Ltd, UK). Venous
blood to measure hematocrit before and after hemodialysis was
collected in an EDTA tube, and subsequently transferred to a
capillary tube and centrifuged for five minutes using a Hawksley
microcentrifuge, after which the hematocrit was determined using
a Hawksley micro-hematocrit reader (Hawksley Ltd, UK).
Plasma cholinesterase, cholesterol and arginine. Blood was col-
lected in lithium heparin tubes and centrifuged for 10 minutes at
2500 rpm. Plasma was then stored at 280°C until assayed. Plasma
cholinesterase activity was measured using a cholinesterase (BTC)
colorimetric analyser kit (Sigma Chemical Co. Ltd. Poole, Dorset,
UK) using a COBAS-BIO analyzer [30]. Plasma cholesterol
concentrations were measured using a Cholesterol CHOD-PAP
method enzyme colorimetric test (Boehringer Mannheim) using
an Hitachi 747 analyzer [31]. Plasma arginine concentrations were
measured using automated orthopthaldehyde derivatisation and
dialysis by ASTED (Gilson Medical Electronics, Villiers le Bel,
France) and then separated from other amino acids using high
performance liquid chromatography. Analytical separation was
achieved using a tertiary gradient system permitting resolution of
the amino acids based on both pKA and hydrophobic interaction
with the column (15 cm, 2.5 mm ID, ODS). A fluorimeter (Gilsen
Medical Electronics) set at 305 to 395 nm excitation, 430 to 470
emission was used as a detector [32]. The coefficient of variation
for the measurement of arginine was 8.9%.
Study design
General. Each study was performed on a separate day and for
each subject studies were separated by at least one week. The
same hand vein was used when repeated studies were performed
in the same subject. Each study that involved patients with
end-stage renal failure related to the same dialysis session during
the week. In addition, the dialysis time and artificial kidney size
and composition were unchanged during the period of study. Also
all patients achieved their clinically assessed dry weight by the end
of each dialysis session. Not all of the patients underwent all of the
protocols, and the details are in Table 1.
Subjects rested semi-recumbent in a quiet room which was
maintained at a constant temperature of between 23 and 25°C.
The dorsal hand vein was cannulated and the LVDT sited. In
control subjects a 21 SWG cannula was inserted under local
anesthesia (1% lidocaine) into an antecubital vein of the opposite
arm for venous blood sampling. Blood pressure and body wt were
measured and blood was withdrawn from the ’arterial’ dialysis
cannula in the patients with end-stage renal failure both before
and after dialysis. In all studies, saline was then infused for 30
minutes to allow the establishment of basal vein size. Vein size
was measured at five minutes intervals throughout each study. In
the control subjects, venous blood was sampled, and blood
pressure was measured, after establishing baseline vein size during
the acetylcholine/GTN dose response study.
Norepinephrine dose response. In resting subjects, in a warm
environment, superficial hand veins have no tone [33]; to investi-
gate venodilation the vein must first be preconstricted. Therefore,
in the first study, after establishing basal vein size norepinephrine
was infused at doubling doses (3 to 192 pmol/min, each dose for
10 min) to determine the dose response relationship. This study
was performed in all subjects and allowed the calculation of a dose
of norepinephrine sufficient to cause ;60% venoconstriction in
subsequent studies.
Endothelial response pre-dialysis. The study was performed . 24
hours after the previous hemodialysis session and ,16 hours
before the next. Oral aspirin (600 mg) was given 30 minutes
before drug infusion to inhibit prostacyclin synthesis [8, 34]. After
saline infusion, norepinephrine was infused sufficient to cause
;60% venoconstriction. Acetylcholine was co-infused at increas-
ing doses (0.1, 1, 10 and 100 nmol/min; each dose for 10 min)
followed by saline for at least 10 minutes to allow the vein to
return to its preconstricted state. Glyceryl trinitrate (GTN; 0.3, 1,
3 and 10 pmol/min; each dose for 10 min) was then infused.
Endothelial response post-dialysis. This protocol was identical to
that used when responses were assessed pre-dialysis except the
study took place 45 to 60 minutes after completion of hemodial-
ysis.
Endothelial response pre-dialysis with co-infused L-arginine or
D-arginine. The pre-dialysis protocol was again followed except
that, after establishing basal vein size and before starting the
norepinephrine infusion, either L-arginine or D-arginine were
co-infused at 100 nmol/min and continued throughout the studies.
Healthy control subjects. After undergoing a norepinephrine
dose response study, healthy control subjects underwent a three
phase single-blind randomized study. Responses to acetylcholine
and GTN were assessed as in the pre-hemodialysis study and, on
separate days at least one week apart, these were repeated with
co-infusion of L-arginine and D-arginine.
For both patients and control subjects, the order of adminis-
tration of acetylcholine and GTN was randomized. However, once
determined, this order was maintained for each subject though
subsequent phases of the study. The order of pre- and post-
dialysis studies and the L- or D-arginine studies were also
randomized.
Data presentation and statistics
Basal vein diameter was calculated by taking the mean of the
last four measurements during saline infusion, and is expressed in
millimeters. Venoconstriction to norepinephrine is expressed as
% constriction [100 3 (resting vein size 2 vein size with norepi-
nephrine)/resting vein size]. Responses to acetylcholine and GTN
are expressed as % reversal of constriction [100 3 (vein size when
agent is infused 2 vein size with norepinephrine)/(resting vein
size 2 vein size with norepinephrine)]. Change in plasma volume
during hemodialysis was calculated according to the following
formula: D plasma volume 5 (100/100-Hctbefore)3(100[Hctbefore
2 Hctafter]/Hctafter) [35]. Changes in blood pressure, hematocrit,
plasma volume and body wt with each dialysis session were
analyzed in all subjects. However, because the pre- and post-
dialysis vein studies took place on different days, the relationship
between the changes in response to acetylcholine and % changes
in blood pressure, hematocrit, plasma volume, arginine and body
wt across dialysis the blood pressure, hematocrit, arginine and
body wt values used data obtained on the relevant study day.
The dose response data are presented as the area under the
curve, expressed as the mean 6 SEM, and examined using Stu-
dent’s paired or unpaired t-test as appropriate. Blood pressure,
basal vein size, hematological and biochemical data are expressed
as the mean 6 SEM, and were analyzed using Student’s paired or
unpaired t-test as appropriate. The relationships between the %
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change of blood pressure and the % change in hematocrit, plasma
volume and plasma concentrations of arginine across dialysis were
analyzed using simple regression analysis. All statistical analysis
was performed using the STATVIEW 5121y software (Brain-
power Inc., Calabasas, CA, USA) for the Apple Macintosh
microcomputer. Values of P # 0.05 were considered statistically
significant.
RESULTS
Norepinephrine dose response
All 12 hemodialysis patients (8 men, 4 women; aged 45 6 5;
range 26 to 65 years) and the 8 control subjects (6 men, 2 women;
age 44 6 6; 26 to 69 years) underwent the dose response study.
There was no difference in the responsiveness to norepinephrine
between the hemodialysis patients and control subjects (P 5 0.96;
Fig. 1).
Basal vein size and % venoconstriction before each study
Basal vein sizes did not differ between studies (Table 2A).
Venoconstriction in response to norepinephrine before the ace-
tylcholine and GTN infusions was also similar (Table 2A), al-
though the pre-constriction before GTN in the L-arginine study
was significantly greater than the pre-dialysis study without L-
arginine (Table 2A). There was no difference in the dose of
norepinephrine required to pre-constrict the vein before or after
dialysis or before infusing acetylcholine or GTN (Table 2A).
Control subjects
Dorsal hand vein dilatation occurred in response to both
acetylcholine (225 6 26; Fig. 2A) and GTN (175 6 27; Fig. 3).
Infusion of L-arginine and D-arginine alone did not affect resting
vein size in control subjects causing a 0 6 1% (P 5 0.49) and
25 6 5% (P 5 0.71) change in vein size respectively. Co-infusion
of L-arginine did not alter venodilation in response to acetylcho-
line (218 6 46; P 5 0.77) or GTN (207 6 23; P 5 0.11).
Venodilation in response to acetylcholine tended to be decreased
during co-infusion of D-arginine (141 6 23; P 5 0.19), although
the GTN responses were unaffected (192 6 29; P 5 0.64).
Endothelial response pre- and post-dialysis
Eight hemodialysis patients (aged 44 6 6; range 26 to 63 years;
Table 1) underwent both parts of this study. All patients achieved
their dry weight during dialysis with an intradialytic fluid loss of
1.9 6 0.2 kg. In patients studied before dialysis, venodilation in
response to acetylcholine was significantly less than in controls
(Fig. 2A, 118 6 27; P 5 0.01). Venodilation in response to
acetylcholine increased after dialysis (Fig. 2B, 208 6 35; P 5 0.001
vs. before dialysis), and the response was not significantly differ-
ent from that of healthy controls (P 5 0.71).
Dilation in response to GTN was similar before (213 6 34) and
after (207 6 40) hemodialysis (Fig. 3; P 5 0.88) or when
compared to control subjects (P 5 0.40 vs. pre-HD; P 5 0.52 vs.
post-HD).
Effect of L- and D-arginine on basal vein size
When co-infused before dialysis, L-arginine (N 5 8; Table 1)
and D-arginine (N 5 4; Table 1) had no significant effect on the
resting vein size, causing a 3 6 4% (P 5 0.30) and 4 6 3% (P 5
0.30) change in vein size, respectively, in patients with end-stage
renal failure.
Endothelial response pre-dialysis with co-infused L-arginine
Eight hemodialysis patients (aged 44 6 6; range 26 to 65 years;
Table 1) underwent both parts of this study. In this group, the
response to acetylcholine with co-infusion of L-arginine pre-
dialysis (290 6 55) was enhanced when compared to pre-dialysis
without L-arginine (150 6 35; P 5 0.09 vs. pre-dialysis; Fig. 4)
with the result that responses were no longer different from
post-dialysis (P 5 0.39) or from healthy controls (P 5 0.71).
Venodilation in response to GTN with co-infusion of L-arginine
(154 6 32) was similar when compared to the pre-dialysis
response without L-arginine (223 6 33; P 5 0.43), to post-dialysis
results without L-arginine (P 5 0.76) or when compared to GTN
responses in healthy controls (P 5 0.62).
Endothelial response pre-dialysis with co-infused D-arginine
Four hemodialysis patients (aged 37 6 7; 26 to 63 years; Table
1) underwent both parts of this study. In contrast to the results
with co-infusion of L-arginine, infusion of D-arginine pre-dialysis
(115 6 36) did not alter responsiveness to acetylcholine (114 6
21; P 5 0.98; Fig. 4). Venodilation in response to GTN with
co-infusion of D-arginine (184 6 43) was similar when compared
to pre-dialysis without D-arginine (205 6 34; P 5 0.78).
Changes in biochemistry and blood pressure across dialysis
Blood pressure fell with hemodialysis (Table 3). However,
despite a decrease in body wt during dialysis, the hematocrit did
not change significantly and the calculated plasma volume de-
creased by only 2 6 2% (Table 3). The % change in body wt with
dialysis correlated with the % change in diastolic (r 5 0.55, P 5
0.02) and mean (r 5 0.52, P 5 0.03) but not systolic arterial
Fig. 1. Effect of norepinephrine on vein size in 12 patients with end-stage
renal failure (F) and 8 age and sex matched control subjects (E). There
is no significant difference in responsiveness to infusion of norepinephrine
(P 5 0.96).
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pressure (r 5 0.47, P 5 0.06). Also, the % change in calculated
plasma volume correlated with the % change in systolic (r 5 0.51,
P 5 0.04), diastolic (r 5 0.56, P 5 0.02) and mean arterial
pressure (r 5 0.55, P 5 0.02) but not % change in body wt (r 5
0.42, P 5 0.09).
Plasma cholinesterase, cholesterol and arginine
Plasma cholinesterase activity increased modestly but signifi-
cantly with hemodialysis (Table 3). However, cholinesterase ac-
tivity in the control subjects was not different from either that
found pre- (P 5 0.76) or post-dialysis (P 5 0.78). Plasma
cholesterol concentrations did not change with dialysis (P 5 0.12).
Plasma arginine concentrations decreased significantly with dial-
ysis (P 5 0.0009). However, the plasma arginine in control
subjects was not statistically different to that found both before
and after dialysis (P 5 0.13 and 0.61, respectively).
The % change in mean arterial pressure between the pre- and
post-dialysis vein studies correlated with the % change in weight
Table 2A.
Pre- and Post-HD
(N 5 8)
Pre-HD with or without
L-arginine (N 5 8)
Pre-HD with or without
D-arginine (N 5 4)
Pre-HD Post-HD 2L-arginine 1L-arginine 2D-arginine 1D-arginine
Hemoglobin g/dl 9.1 6 0.4a 8.7 6 0.7a 8.9 6 0.3a 8.7 6 0.6a 7.9 6 0.3a 7.9 6 0.2a
Basal vein size mm 0.7 6 0.2 0.7 6 0.2 0.7 6 0.2 0.5 6 0.2 0.5 6 0.2 0.3 6 0.1
% Venoconstriction to NE before GTN 66 6 4 65 6 3 65 6 4c 74 6 6b 71 6 6 65 6 5
% Venoconstriction to NE before ACh 62 6 3 62 6 3 62 6 3 67 6 5 67 6 4 62 6 4
Dose of NE before GTN pmol/min (median; range) 23.7; 6–96 28.2; 6–192 24.0; 6–192 11.1; 3–24 17.1; 6–96 26.7; 12–78
Dose of NE before ACh pmol/min (median; range) 21.9; 6–192 24.0; 6–192 24.0; 6–96 11.4; 3–30 20.1; 6–192 28.5; 3–48
Table 2B.
Control subjects (N 5 8) 1L-arginine 1D-arginine
Hemoglobin g/dl 13.6 6 0.4
Basal vein size mm 0.9 6 0.2 0.9 6 0.2 0.9 6 0.2
% Venoconstriction to NE before GTN 64 6 4 63 6 1 63 6 3
% Venoconstriction to NA before ACh 62 6 3 64 6 3 61 6 3
Dose of NE before GTN pmol/min (median; range) 33.9; 3–384 40.2; 6–383 40.5; 6–383
Dose of NE before ACh pmol/min (median; range) 29.1; 3–384 38.1; 3–498 39.3; 6–383
Abbreviations are: norepinephrine (NE); acetylcholine (ACh); glyceryl trinitrate (GTN).
a P , 0.01 vs. control, b P 5 0.07 vs. control, c P 5 0.007 vs. pre-dialysis 1L-arginine
Fig. 2. Percentage reversal of venoconstriction
by acetylcholine (A) in 8 patients before
hemodialysis (M) and 8 control subjects (E)
and (B) in 8 patients before (M) and after
hemodialysis (f). Before hemodialysis the
response is impaired compared with that of
control subjects (P 5 0.01) and is enhanced by
hemodialysis (P 5 0.001).
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(r 5 0.79, P 5 0.02; Table 4) but not the % change in arginine (r 5
0.35, P 5 0.40), % change in response to acetylcholine (r 5 20.29,
P 5 0.49); or the % change in hematocrit (r 5 0.44, P 5 0.28).
DISCUSSION
This study shows, to our knowledge for the first time, that there
is impaired responsiveness to the endothelium dependent dilator,
acetylcholine, but not to the endothelial independent agent,
glyceryl trinitrate (GTN), in the veins of patients with end-stage
renal failure. We have also demonstrated that this endothelial
dysfunction is normalized by hemodialysis and stereospecifically
reversed by the nitric oxide synthase substrate L-arginine. These
data suggest that end-stage renal failure is associated with impair-
ment of the L-arginine/nitric oxide pathway. Although we did not
address this issue directly, our results are consistent with a role for
a circulating inhibitor (or inhibitors) of nitric oxide synthase that
accumulates in end-stage renal failure, is cleared by hemodialysis,
and reversed by L-arginine. Endogenous metabolites of L-argi-
nine, such as ADMA, L-NMMA and methylguanidine, are known
to inhibit nitric oxide synthase [14–16, 20] and accumulate in
patients with end-stage renal failure [12, 14, 36]. However, the
degree of ADMA accumulation within the plasma appears vari-
able [36]. Although many nitric oxide synthase inhibitors may be
involved and may act synergistically [14, 19], ADMA is a partic-
ularly plausible candidate for the dialysis-dependent changes in
Fig. 3. Percentage reversal of venoconstriction by glyceryl trinitrate in 8
patients with end-stage renal failure before (M) and after hemodialysis
(f), and in 8 control subjects (E). There are no significant differences
between the response before and after hemodialysis (P 5 0.88) or to
control subjects (P 5 0.52).
Fig. 4. Percentage reversal of venoconstriction by acetylcholine before
hemodialysis in 8 patients with end-stage renal failure with (F) and
without co-infusion of L-arginine (E) and in 4 patients before hemodial-
ysis with (f) and without co-infusion of D-arginine (M). The response to
acetylcholine is enhanced with co-infusion of L-arginine (P 5 0.09).
However, there is no significant change in the response to acetylcholine
when D-arginine is infused pre-hemodialysis (P 5 0.98).
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endothelial function observed here, because of its clearance by
hemodialysis [14, 19, 36] and because it is concentrated within the
endothelial cell [37]. Our findings complement the recent descrip-
tions of increased generation of nitric oxide during hemodialysis
[38–40].
Normalization of the impaired pre-dialysis acetylcholine re-
sponses may have several explanations other than changes in nitric
oxide generation. First, differences in basal vein size or in the
degree of venoconstriction in response prior to the acetylcholine
or GTN infusions might have confounded the results. However,
the same vein was used in each subject and both the basal vein size
and the degree of venoconstriction in response to norepinephrine
were similar in all parts of this study (Table 2). Thus, all studies
investigating the reversal of venoconstriction in response to
acetylcholine, and the GTN response before and after hemodial-
ysis, were performed under similar conditions, and a confounding
effect is, therefore, unlikely.
Second, forearm blood flow responses to acetylcholine infused
into the brachial artery are dependent on plasma cholinesterase
activity [41] with high cholinesterase activity reducing responsive-
ness to acetylcholine. In our experiments plasma cholinesterase
activity increased significantly with dialysis. However, neither pre-
nor post-dialysis cholinesterase activity was significantly different
from that found in healthy control subjects. Nevertheless, if the
small increase in plasma cholinesterase activity that we observed
with dialysis has an important effect, it would be to increase
degradation of acetylcholine and reduce its efficacy after dialysis
and it cannot, therefore, explain our findings. Also, altered plasma
cholinesterase activity would not account for selective enhance-
ment of the pre-dialysis response with L-, but not D-arginine.
Third, hypercholesterolemia has been reported to cause an
impaired endothelial response to acetylcholine in resistance ves-
sels [42]. However, plasma concentrations of cholesterol tended to
increase across dialysis, although not significantly, and so should
not contribute to the enhanced response to acetylcholine. Also, in
contrast to responses in forearm resistance vessels, hypercholes-
terolemia does not appear to alter the endothelial response to
acetylcholine in hand veins [43].
Fourth, the altered responsiveness to acetylcholine with hemo-
dialysis may occur as a result of a reversible change in function of
the muscarinic receptor, as a consequence of mediators of endo-
thelial dependent dilation other than nitric oxide [44], or because
of altered vein wall characteristics. However, the enhancement in
the response to acetylcholine before dialysis by co-infusion of
L-arginine but not D-arginine suggests that the difference relates
to a specific effect on nitric oxide [8].
Fifth, altered adrenergic function has been implicated in car-
diovascular instability in patients undergoing hemodialysis [3]
although mainly in diabetic subjects [45]. In our studies, we did
not observe any difference in the dose response to norepinephrine
for the dialysis patients compared to control subjects (Fig. 1).
Also, the dose of norepinephrine required to cause ;60% veno-
constriction either before or after dialysis was similar (Table 2A),
implying that venous responsiveness to norepinephrine did not
change with dialysis. Thus, our results are unlikely to be explained
by altered adrenergic tone.
Sixth, increases in core temperature during dialysis may cause
vasodilation and cardiovascular instability during hemodialysis
[3]. Patient core temperature was not measured during these
studies and heat induced vasodilation may have a potentially
confounding influence. However, temperature mediated vasodi-
lation is not thought to be mediated through the nitric oxide
synthase pathway [46]. Studies showing the enhancement of the
response to acetylcholine by co-infusion of L- but not D-arginine
were undertaken before dialysis, so dialysis-induced temperature
change would not influence these results. In addition, the similar
resting vein size before and after dialysis and the similarity in
venous responses to norepinephrine argue against a change in
core temperature as the explanation of our findings, although the
pathophysiology of temperature change during dialysis needs to
be investigated further.
In health there is an excess of intracellular L-arginine to act as
a substrate for nitric oxide synthase [8]. Data regarding plasma
L-arginine concentrations in end-stage renal failure are contra-
dictory [47–50]. Our results suggest that plasma L-arginine levels
are normal in end-stage renal failure. However, plasma L-arginine
does not clearly reflect the intracellular pool, which appears to be
reduced in hemodialysis patients [48, 49]. Low intracellular con-
centrations of L-arginine render the endothelial cell more suscep-
tible to the effects of competitive nitric oxide synthase inhibitors
[20, 51], which are also concentrated within the endothelial cell
[37], and might contribute to the impaired acetylcholine response
pre-dialysis despite normal plasma L-arginine concentrations.
Although nitric oxide does not regulate tone in human dorsal
hand veins under basal experimental conditions [8], this may not
be the case during activity. Also, human muscle capacitance
vessels do exhibit basal tone [5, 6, 21, 52]. In animals, nitric oxide
Table 3. Change across individual hemodialysis sessions
Before HD
(N 5 16)
After HD
(N 5 16)
Control
(N 5 8)
Systolic blood pressure
mm Hg
133 6 6 118 6 9a 114 6 6
Diastolic blood pressure
mm Hg
79 6 4 70 6 4a 69 6 3
Mean arterial pressure
mm Hg
97 6 4 86 6 5a 84 6 4
Hematocrit % 28 6 1 29 6 1
Weight kg 67.5 6 2.5 65.5 6 2.5b
Plasma cholesterol mg/dl 181 6 8 185 6 12 212 6 19
Plasma cholinesterase AU 6894 6 467 7381 6 537b 7137 6 577
Plasma arginine mg/dl 2.4 6 0.4 1.4 6 0.2b 1.5 6 0.1
Abbreviation HD is hemodialysis.
When comparing before and after dialysis results: a P , 0.05, b P , 0.01
Table 4. Parameters when paired to the appropriate vein study
Before HD
(N 5 8)
After HD
(N 5 8)
Systolic blood pressure mm Hg 137 6 10 120 6 12
Diastolic blood pressure mm Hg 79 6 6 71 6 7
Mean arterial pressure mm Hg 98 6 7 87 6 9
Hematocrit % 28 6 16 28 6 18
Weight kg 69.0 6 3.5 66.5 6 3.5b
Plasma cholesterol mg/dl 174 6 12 181 6 12a
Plasma cholinesterase AU 7725 6 661 7425 6 781
Plasma arginine mg/dl 2.3 6 0.4 1.5 6 0.4
HD is hemodialysis.
a P , 0.05, b P , 0.01
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is known to contribute to venous tone [53–57]. Therefore, clear-
ance of nitric oxide synthase inhibitors may help explain the
inappropriate venodilation seen during hemodialysis [5, 6] and
contribute to dialysis related hypotension [3].
Although we were able to demonstrate an improvement in
endothelial dilator function across dialysis we were unable to
demonstrate a significant relationship between changes in blood
pressure and changes in endothelial function. There may be
several reasons for this. First, the experimental design imposed
limitations on the data that could be collected as it would be
impractical to undertake the pre- and post-dialysis study on the
same day. As a consequence when we compared the measure-
ments of weight, blood pressure, hematocrit and response to
acetylcholine, the results before and after dialysis are from
different days which, because of individual day-to-day variation,
reduces the power of this part of the analysis. Indeed, when
examining our results in this manner, apart from the significant
change in endothelial function we were only able to demonstrate
a change in body wt with dialysis. Second, changes in circulating
volume during dialysis are dependent on multiple factors includ-
ing hydration state and ultrafiltration rate, which may explain why
there was no correlation between % change in plasma volume and
% change in body wt. In addition, the limitations imposed on the
study may account for the absence of a significant correlation
between % change in mean arterial pressure and the % change in
plasma volume, % change in the acetylcholine response or %
change in body wt. Third, plasma concentrations of the inflam-
matory cytokines interleukin-1 (IL-1) and tumor necrosis factor
alpha (TNF-a) are chronically elevated in end-stage renal disease
patients undergoing dialysis and IL-1 increases further during
hemodialysis [58]. Interleukin-1 and TNF-a also cause the accu-
mulation of inducible nitric oxide synthase within the vascular
smooth muscle [58], although nitric oxide production only occurs
after several hours of exposure to IL-1 and TNF-a. Therefore,
IL-1 and TNF generation as a consequence of hemodialysis would
not explain the observed early generation of nitric oxide [39, 40].
However, inducible nitric oxide synthase has been demonstrated
to be inhibited by analogs of L-arginine, such as ADMA and
L-NMMA [20], and clearance of these inhibitors by hemodialysis
may substantially increase the generation of nitric oxide via the
chronically up-regulated inducible nitric oxide synthase enzyme
during the early part of hemodialysis. This hypothesis is supported
by the ex vivo observations that uremic plasma inhibits cytokine-
stimulated inducible nitric oxide synthase, that after dialysis there
is a reduced inhibitory effect and, also, that these effects are
independent of the hemodialysis technique used [19]. Therefore,
although the improvement of endothelial function with dialysis
reflects the removal of nitric oxide synthase inhibitors, the main
consequence of the clearance of these inhibitors may be to
increase nitric oxide generation via the inducible nitric oxide
synthase enzyme. This mechanism would account for the in-
creased generation of nitric oxide observed during the early and
late stages of hemodialysis [38–40] and provide a mechanism for
dialysis hypotension, although other potential mechanisms, including
direct hemodialysis membrane activation of platelets, neutrophils
and monocytes, may have an additional role [40]. Further studies are
needed to assess whether altered endothelial function with dialysis
per se contributes to hemodialysis related hypotension.
Besides contributing to hemodialysis associated hypotension
after their removal, the accumulation of endogenous inhibitors of
nitric oxide synthase may have an important role in the generation
or maintenance of hypertension in chronic renal failure. In a rat
model, chronic inhibition of the nitric oxide synthase pathway
causes hypertension and glomerular sclerosis [59]. In human
subjects, systemic inhibition of nitric oxide synthase also increases
blood pressure [60]. In addition, control of hypertension in
patients with end-stage renal failure is partially dependent on
dialysis dose [61]. Also, venous tone appears to be elevated in
patients with end-stage renal failure [52], although this may be
restricted to patients with hypertension [62]. By increasing venous
tone, and thereby increasing venous return, endogenous inhibitors
of nitric oxide synthase may play a role in the increase in blood
pressure found between hemodialysis sessions that is not related
to increasing fluid load [63, 64] and in the hypertension associated
with renal failure.
In animal models, nitric oxide has an antiproliferative effect
[65] and inhibition of nitric oxide synthase promotes the develop-
ment of atherosclerosis [66, 67]. Plasma ADMA concentrations
are increased in high cholesterol fed rabbits [68] and in neointimal
cells [69]. In diseases primarily associated with abnormalities in
resistance or conduit vessels similar abnormalities are found in
hand veins [24]. Should the endothelial dysfunction demonstrated
in our study also occur in resistance vessels, this may contribute to
the atherosclerotic process in patients with chronic renal failure.
Impairment of endothelial function by the accumulation of inhib-
itors of nitric oxide synthase may, therefore, contribute to the
development of atherogenesis in end-stage renal failure and thus
to the high cardiovascular morbidity and mortality found in these
patients.
In summary, we have demonstrated for the first time that there
is impaired endothelial cell dilator function in patients with
end-stage renal failure undergoing renal replacement therapy by
hemodialysis. This endothelial dysfunction is corrected by dialysis
and stereospecifically improved by infusion of the nitric oxide
substrate L-arginine, but not its inactive enantiomer D-arginine.
Previous studies have demonstrated that endogenous inhibitors of
nitric oxide synthase accumulate in chronic renal failure [12, 14]
and are cleared by dialysis [14, 19]. Our results suggest an
important functional role for such inhibitors in patients with
end-stage renal failure. Impairment of endothelial function may
contribute to the hypertension and atherogenesis associated with
end-stage renal failure. Furthermore, enhancement of endothelial
function by clearance of nitric oxide synthase inhibitors may be of
importance in hemodialysis related hypotension. It may be of
value to further study the role of L-arginine as a therapeutic agent
in renal failure.
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